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ABSTRACT
Background Obsessive–compulsive disorder (OCD) 
is a major cause of disability in western country and 
responsible for severe impairment of quality of life. About 
10% of patients present with severe OCD symptoms 
and require innovative treatment such as deep brain 
stimulation (DBS). Among possible targets, the non- 
motor subthalamic nucleus (STN) is a key node of the 
basal ganglia circuitry, strongly connected to limbic 
cortical areas known to be involved in OCD.
Method We analysed, in a prospective, observational, 
monocentric, open label cohort, the effect of chronic 
non- motor STN- DBS in 19 patients with treatment- 
resistant OCD consecutively operated in a single centre. 
Severity of OCD was evaluated using the Yale and 
Brown Obsessive–Compulsive Scale (YBOCS). YBOCS 
scores at 6, 12 and 24 months postoperatively were 
compared with baseline. Responders were defined by 
>35% improvement of YBOCS scores. Global Assessment 
Functioning (GAF) scale was used to evaluate the impact 
of improvement.
Results At a 24- month follow- up, the mean YBOCS 
score improved by 53.4% from 33.3±3.5 to 15.8±9.1 
(95% CI 11.2–20.4; p<0.0001). Fourteen out of 19 
patients were considered as responders, 5 out of 19 
being improved over 75% and 10 out of 19 over 
50%. GAF scale improved by 92% from 34.1±3.9 to 
66.4±18.8 (95% CI 56.7–76.1; p=0.0003). The most 
frequent adverse events consisted of transient DBS- 
induced hypomania and anxiety.
Conclusion Chronic DBS of the non- motor STN is an 
effective and relatively safe procedure to treat severe 
OCD resistant to conventional management.
INTRODUCTION
Obsessive–compulsive disorder (OCD) is a major 
cause of disability worldwide1 and responsible 
for severe impairment of quality of life. It is 
one of the most frequent psychiatric conditions 
just after depression and affects 2%–3% of the 
population. OCD is characterised by recurrent 
unwanted ideas, images or impulses (obsessions), 
and repetitive stereotyped behaviours or mental 
acts (compulsions), often intended to neutralise the 
anxiety induced by the obsessions. Several obses-
sions types can be defined2 3 like contamination, 
pathological doubt, somatic, need for symmetry, 
aggressive, sexual and other that will lead to asso-
ciated compulsions such as counting, checking, 
hoarding, washing, symmetry and precision. These 
symptoms are supported by different neuronal 
networks4 5 that may be of therapeutic interest and 
the variability of symptoms mirror their heteroge-
neity in response to conventional treatment. About 
30%–40% of patients present with severe (Yale 
and Brown Obsessive Compulsive Scale (YBOCS) 
24–31) to very severe (YBOCS 32–40) OCD symp-
toms.5 6
OCD usually tends to be chronic and might 
require long- term medication and cognitive- 
behaviour therapy (CBT). Indeed, first- line treat-
ments for OCD consist of CBT, including exposure 
and ritual prevention associated or not with medi-
cations, particularly serotonin reuptake inhibitors.
The above- mentioned conventional treatment 
can lead to satisfactory responses but improvement 
after medication and CBT is usually partial and 
consequently, a 35% reduction in YBOCS severity 
scores can be seen as a good response to the treat-
ment and represents a typical response criterion in 
pharmacological trials. Despite conventional treat-
ment, approximately 10% of patients with OCD 
remain severely disabled.7
Multimodal functional imaging studies have 
led to a better definition of key brain structures 
involved during the expression of OCD symp-
toms.8–10 The orbital frontal region, the dorsolat-
eral prefrontal cortex and the dorsal cingulum have 
been identified as key areas during the occurrence 
of OCD. At the subcortical level, bundles going 
through the anterior capsule have been identified 
as key neuronal streams that connect the thalamus 
to the orbitofrontal region. The accumbens nucleus 
has also been seen as a pivotal node due to its role in 
the reward system that is supposedly overactivated 
in OCD.
The better comprehension of the neuronal 
circuitry that links motor, cognitive and limbic 
cortex to the thalamus and the basal ganglia has 
rendered new surgical strategies possible. In 1999, 
Nuttin et al11 have proposed to replace lesions of 
the anterior limb of the capsule by deep brain stim-
ulation (DBS), a surgical therapy developed to treat 
movement disorders.12
One of the key nodes of this neuronal circuitry is 
the subthalamic nucleus (STN), which receive not 
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Neurosurgery
only hyperdirect connections from the motor and non- motor 
cortex, but also indirect inhibitory connections from the stri-
atum through the Globus Pallidus externus.13 14 From a clinical 
stand point, a posteroanterior gradient from motor, cognitive 
and limbic territories can explain why stimulations of the poste-
rior and dorsal part of the STN in patient with Parkinson’s 
disease (PD) can alleviate motor symptoms, whereas the more 
anterior and ventral site of stimulation can impact non- motor 
symptoms of PD.15
This was illustrated by the report of three cases of patients 
with PD, who also suffered from OCD as a comorbidity, and who 
improved after STN- DBS.15 16 In those cases reports, the motor 
STN was the original target but the leads were a little bit more 
anteriorly placed, at the junction between motor and non- motor 
STN (noM- STN). Mallet et al17 reported in 2008 the results of 
the French multicentre, double- blind, cross- over control study 
(STOC study) assessing the effect of noM- STN- DBS to treat 
patients with severe OCD. They mainly showed that the YBOCS 
was significantly improved by 31% on average as compared with 
Off condition.
Following this study, we prospectively followed, in an open, 
observational, prospective, monocentric cohort, 19 consecutive 
patients suffering from severe OCD refractory to conventional 
management in order to (1) confirm the potential effective-
ness of STN- DBS at short- term and long- term follow- ups (24 
months) and (2) asses the safety of STN- DBS for OCD.
MATERIALS AND METHODS
All patients gave informed consent before their inclusion in the 
surgery programme. Inclusion and exclusion criteria strictly 
followed those previously used in the STOC study.17 One of the 
senior coauthors asked the French National Ethical Committee 
to approve such procedure and a multidisciplinary committee 
selected the cases to be enrolled.18 Most of them were referred 
to by independent psychiatrists.
Inclusion criteria and ethics (see table 1)
Surgery
The surgical technique used replicated that routinely used to 
treat patients with PD with STN- DBS12 except that the OCD 
target was slightly more anterior and medial.19 In the first 11 
patients, the indirect targeting of the motor STN (M- STN) was 
determined on the ventriculography schema fused with the MRI 
and corresponded to the following coordinates: 7 of 12 of the 
anterior–posterior commissural (AC- PC) length posterior to 
the AC, 11–12 mm lateral to the midline and 3 mm below the 
AC- PC line. In patients with OCD, the non- motor- STN (noM- 
STN) was targeted 2 mm anterior and 1 mm medial to the motor 
target. Final DBS leads (model 3389, Medtronic, Minneapolis, 
USA) positioning was refined after microelectrode recordings 
and microstimulation. More precisely, trajectories that showed 
STN neuronal activities that responded to proprioceptive move-
ments of the wrist or the leg, indicating the sensorimotor subre-
gion of the STN, or those in which intraoperative stimulation 
induced motor contraction (indicating capsular current diffusion 
or too lateral implantation) or ipsilateral eye adduction (indi-
cating diffusion to oculomotor fibre tract or too medial implan-
tation), were rejected.
For the last eight patients, direct targeting was performed based 
on the visualisation of the STN on 3T MRI scans (T2 sequences). 
To that aim, we first drew a line at the most anterior border of 
the red nucleus, and this line delineated, when crossing the STN, 
the motor target position. We then marked the point located 
2 mm anterior and 1 mm medial to that motor target, in the 
anteroposterior direction of the main axis of the STN.17 19 Then, 
a frameless, robot- assisted surgery was performed using ROSA 
robotic arm and Rosanna software (Zimmer Biomet, USA) that 
allowed the fusion of all imaging modalities including preopera-
tive CT scan, T1 and T2 MRI and intraoperative, tele X- ray. All 
patients had postoperative CT scan before the implantation of 
the battery (Kinetra then Activa PC, Medtronic, Minneapolis, 
USA) that occurred 2 days after lead implantation. Surgery was 
performed in all cases except one under local anaesthesia that 
allowed intraoperative checking for side effects and for possible 
acute therapeutical effects.
Clinical evaluation and outcome measures
The severity of OCD was evaluated with the YBOCS. Patients 
were defined as responders if their YBOCS scores decreased 
by at least 35%. The social and psychological functioning was 
assessed with the Global Assessment Functioning (GAF) scale.
All patients were prospectively evaluated at 6, 12 and 24 
months than once a year. However, patients were also visited 
when needed to adjust settings parameters. Neither the clini-
cians nor the patients were blinded during the study. Medica-
tions could be adjusted whenever required. However, limited 
therapeutical adjustments were possible due to the pharmaco- 
resistance of the OCD symptoms already experienced during the 
preoperative period.
All adverse events (AEs) related to surgery and to stimulation 
were systematically reported in a database.
Table 1 : Main inclusions and exclusions criteria
Inclusion criteria Exclusion criteria
OCD defined by DSM- IV Yes Yes: bipolar disorder, 
schizophrenic disorder; 
current substance abuse 
or dependence (except 
nicotine)
Cluster A/B personality 
disorders
NA Yes
Recent severe depression NA Yes
 ► MADRS score >20
 ► Risk of suicide 
(MADRS item-10 score 
>2)
Age >18 NA
YBOCS >25 NA
GAF <45 NA
CGI >4 NA
Medications Failure of three serotonin 
reuptake inhibitors 
including clomipramine 
after a minimum of 
12 weeks of adequate 
treatment and two 
augmentation strategies
NA
Psychotherapy Failure of cognitive 
behavioural therapy 
conducted during at least 1 
year with two therapists
NA
CGI, Clinical Global Impression; DSM- IV, Diagnostic And Statistical Manual OF 
mental Disorders- 4 th edition; GAF, Global Assessment Functioning; MADRS, 
Montgomery- Asberg Depression Rating Scale; NA, not applicable; OCD, obsessive–
compulsive disorder; YBOCS, Yale and Brown Obsessive–Compulsive Scale .
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Study design and statistics
This was an open, prospective, observational cohort followed at 
a long- term follow- up focusing mainly on the safety and efficacy 
of noM- STN- DBS. All patients and clinicians were aware of the 
stimulation conditions. All values were expressed as mean±SD. 
YBOCS scores were compared at 6, 12 and 24 months with base-
line scores using an analysis of variance Friedman test followed 
by Dunn’s multiple tests. GAF scores were compared at 24 
months using a Wilcoxon matched pairs signed- rank test. The 
gender distribution among the responders was studied using a 
Fisher exact test. Statistical tests were performed using software 
GraphPad InStat V.3 (GraphPad Software, California, USA). A 
difference was considered statistically significant for a p value 
<0.01.
Leads and contact locations
A postoperative stereotactic 1.5 T MRI or, for the last eight 
cases, a postoperative CT scan was obtained in all patients. All 
postoperative images were plotted onto an adaptable atlas devel-
oped by Yelnik et al.20 This 3D atlas allowed localising each lead 
and active contact used during the chronic phase of stimulation 
within the subregion of the STN (figure 1).
Parameters settings
Postoperatory settings of stimulation parameters followed a 
pre- established procedure and consisted of successive trials of 
monopolar stimulation, beginning with the most ventral pair 
of contacts and followed by the more dorsal contacts. Voltage 
was increased progressively by 0.5 V steps until side effects were 
obtained.
All stimulators were set at a frequency of 130 Hz and at a 
pulse width of 60 µs using a single monopolar, cathodal contact 
(case being positive).
RESULTS
Between 2005 and 2013, 19 patients (7 male and 12 female indi-
viduals) have been operated in our neurosurgery department. 
The first four were enrolled in the STOC study and two patients 
were enrolled in a separate multicentric study (‘Unibil study’ and 
STOC 2). The clinical features of the patients are summarised in 
table 2. In this cohort, medications could be modified before and 
after surgery, but in fact, those medications were not changed to 
an extent that could in our opinion have changed the evolution 
of their disease, mainly because all those medications were used 
before surgery without success.
DBS effects on YBOCS and GAF scores
Data are reported in table 3. In patient 2, the stimulation was 
stopped at 6 months due to personality disorders that were 
revealed during the follow- up and not detected at the time of 
the enrolment in the STOC (
Stimulation dans le Trouble Obsessionnel Compulsif)
After 6 months of chronic stimulation, the mean YBOCS score 
decreased from 33.2±3.6 to 18.2±9.5 points (95% CI 13.4–
22.9; 44%; p<0.0001). Ten patients out of 18 were considered 
as responders, defined as a YBOCS score improved by at least 
35 %, with a mean decrease of the YBOCS score of 65% (33 
vs 11.2, respectively) as compared with 8 patients who did not 
respond (YBOCS: 25.4%, 30.3 vs 24).
At a 12- month follow- up, the mean YBOCS score decreased 
from 33.2±3.6 to 17.3±10.2 points (95% CI 12.3–22.4; 49.4%; 
p<0.0001). At the subgroup level, 2 additional patients were 
considered as responders (patients 8 and 9) with a mean decrease 
of the YBOCS score of 60.5% (YBOCS: 33 vs 10.2), whereas 
patient 11 did not respond any more. The non- responder 
subgroups had a mean decrease in the YBOCS score of 13.2% 
(YBOCS: 30.3 vs 24.2).
At a 24- month follow- up, the mean YBOCS score decreased 
from 33.3±3.5 to 15.8±9.1 points (95% CI 11.2–20.4; 53.4%; 
p<0.0001). At the subgroup level, three additional patients 
were considered as responders (patients 4, 11 and 15) with a 
mean decrease of the YBOCS score of 58.3% (YBOCS: 33 vs 
11.8). The non- responders subgroup had a mean decrease in the 
YBOCS score of 9.3% (YBOCS: 30.3 vs 22.6).
Importantly, no patient worsened after stimulation between 
baseline and 24 months follow- up. At 24 months, 14 out of 19 
(we included for final analysis, patient #2 even if he was not 
analysed at 24 months) were considered as responders, with 5, 5 
and 4 patients being improved more than 75%, 50% and at least 
35%, respectively (figure 2).
The GAF scale was significantly improved from 34.1±3.9 
to 66.4±18.8 (95% CI 56.7–76.1; improvement of 92%) at a 
24- month follow- up (p=0.0003) (figure 3).
Responders versus non-responders
At a 2- year follow- up, 14 patients had an improvement of at 
least 35% and were considered as responders. No differences 
regarding age at onset, at surgery and duration of the disease 
were noticed. The ratio of female/male was significantly higher 
in the responder group (p=0.0018) and all female individuals 
were responding to the therapy (table 5).
Regarding the type of obsessions and compulsions, no statisti-
cally significant differences were shown between the two groups 
of patients.
Stimulation parameters and active contacts
The Medtronic 3389 lead model was used in all patients, 
connected to a Kinetra or an Activa PC. Voltage ranged from 1.1 
to 3.6 and was adapted if required. Stimulation of the non- motor 
(limbic- associative) territories could be limited by behavioural 
side effects like disinhibition of behaviour, agitation, anxiety, 
euphoria and mania. To avoid them, the increase in stimulation 
parameters was performed progressively in an inpatient setting 
in our institution in the immediate postsurgical period. In most 
of the cases, after the clinical response, the voltage was set and 
remained stable over time. At the last follow- up, nine patients 
Figure 1 Location of active contacts implanted in the non- motor STN 
and plotted onto the Yelnik and Bardinet atlas. (A) 3D representation of 
two STN with functional subdivision (yellow=limbic territory, pink: cognitive 
territory, green: motor territory). (B–D) Axial, sagittal and coronal 2D views, 
respectively. STN, subthalamic nucleus.
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had a monopolar stimulation and eight had two cathodes turned 
ON, the case being positive in all cases. One patient was stim-
ulated using a bipolar mode. Contacts 1 and 5, located at the 
ventral part of the noM- STN, were the most preferred contacts 
used in 14 patients (table 6).
Patients with STN- DBS in the noM- STN typically develop 
euphoria, agitation, hyperactivity, decrease in sleep time and 
disinhibited behaviours, as also described in PD21 22 and in our 
experience, this is indicative of best electrode localisation. Acute 
psychotropic effects of STN- DBS seen within 24 hours after 
switching on or increasing stimulation amplitude is used as a 
positive predictor of localisation in noM- STN and improvement 
in OCD, similar to dyskinesia that can guide towards motor 
STN in PD. The main side effects of STN- DBS in anteromedial 
localisation of STN electrodes are ipsilateral eye adduction as a 
consequence of current diffusion to the oculomotor fibre tract. 
In such localisation, the patients can also subjectively complain 
about double vision, which can be avoided by decreasing stimu-
lation intensity, choosing a more dorsal contact or using bipolar 
stimulation. Double monopolar stimulation is rarely used in the 
absence of offside effects if two adjacent contacts both induce 
beneficial but too small effects without side effect.
Adverse events
Most of the AEs were related to the simulation and consisted 
of hypomania in three cases and anxiety reactions in three 
cases. Impulsivity, irritability and behavioural disinhibition 
were the most frequent AE encountered during post op period. 
Four patients experienced contralateral dyskinesia during the 
ramping up of parameters settings that resumed just after stimu-
lation adjustment. One patient showed contralateral pyramidal 
contraction at 3 V that also vanished after decreasing the ampli-
tude of stimulation. AEs related to surgery were represented by 
an extracranial infection at the level of the lead that required 
a surgical cleaning and antibiotics for 3 months without any 
removal of the lead. Another patient suffered from a postop-
erative left thalamic contusion with a dysarthria at a 6- month 
follow- up, mild but persistent at the last follow- up. No seizures 
were noticed in any of the patients (table 7).
During the first year of follow- up, two patients had transient 
suicidal ideation. However, at the time of finalising this report, 
two patients died from suicide at 3- year and 5- year follow- ups. 
The first one was a woman who experienced a 90% reduction in 
the YBOCS at 2 years. She committed suicide in the context of 
a reactive depression unrelated to her OCD. The second patient 
Table 2 Clinical features of the patients
Patient
(gender/age)
Age at 
onset 
(years)
Duration 
disease (years) Pre- op meds (mg/D) OCD type Comorbidity
Pre- op YBOCS
(O+C)
1 (M/39) 21 18 Fluvoxamine 200 mg; clonidine 0.3 mg; pimozide 
1 mg
A Tourette 18+19=37
2 (M/51) 16 35 Fluoxetine 20 mg; prazepam 20 mg C Personality disorder; ICD 
(kleptomania)
18+17=35
3 (F/43) 11 32 Risperidone 4 mg; sertraline 100 mg; alprazolam 
0.75 mg
C- R   16+20=36
4 (F/42) 17 25 Fluoxetine 20 mg; venlafaxine 75 mg; valproate 
1000 mg; levomepromazine 25 mg; bromazepam 
6 mg
W Kleptomania (ICD); depression; 
past suicide attempts
15+15=30
5 (F/34) 10 24 Paroxetine 60 mg W   17+17=34
6 (F/35) 20 15 Clobazam 5 mg; prazepam 10 mg; lamotrigine 75 
mg; escitalopram 30 mg; zolpidem 10 mg
C Left temporal surgery (3 y before 
DBS) for refractory epilepsy
14+15=29
7 (F/37) 32 5 Venlafaxine 150 mg; bromazepam 9 mg C- R   14+18=32
8 (F/52) 27 25 Clomipramine 50 mg; citalopram 20 mg; 
hydroxyzine 200 mg; zopiclone 7.5 mg
W   20+20=40
9 (F/38) 27 11 Sertraline 100 mg; clonazepam 2 mg; zolpidem 10 
mg; piribedil 150 mg
W   18+18=36
10 (M/36) 19 17 Paroxetine 50 mg W Anankastic personality 17+15=32
11 (F/40) 25 15 Fluvoxamine 200 mg; clomipramine 75 mg; 
oxcarbazepine 600 mg; clonazepam 2 mg; 
zolpidem 10 mg if needed
W History of eating disorder, 
alcoholism, 1 seizure; pruritus
19+17=36
12 (F/54) 32 22 Paroxetine 50 mg; lorazepam 3 mg; zopiclone 
7.5 mg
C Depression; Minkowski- 
Chauffard syndrome with 
splenectomy; osteoporosis
17+16=33
13 (M/27) 17 10 Sertraline 150 mg; amisulpride 300 mg C- R Hypersomnia 18+20=38
14 (M/34) 21 13 Buspirone 30 mg; cyamemazine 150 mg; 
clomipramine 187.5 mg
C- R   16+16=32
15 (F/31) 7 24 Venlafaxine 75; levothyroxine 125 mg/j C Hypothyroidia; ICD 
(dermatillomania)
16+18=34
16 (M/46) 20 26 Paroxetine 40 mg C- H Social phobia 15+18=33
17 (M/55) 16 39 Acamprosate 1998 mg C- R History of addiction and suicide 
attempt history of tuberculosis
15+16=31
18 (F/36) 18 18 Escitalopram 30 mg A Baby birth at M10 12+13=25
19 (F/33) 12 21 Venlafaxine 225 mg; alprazolam 0.375 mg C ICD (dermatillomania) 15+15=30
*OCD type: C: doubt/checking; W: contamination/washing; A: aggressive; H: hoarding; R: repetitive, just right obsessions.
ICD, Impulsive Compulsive Disorder; OCD, obsessive–compulsive disorder; Pre- op, preoperative; YBOCS, Yale and Brown Obsessive–Compulsive Scale.
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was not improved at a 2- year follow- up and asked for suicide 
assistance in a different European country without our knowl-
edge, and died. We were not aware of this patient’s request and 
were not informed when the patient passed away (for more 
details, see the online supplemental material).
DISCUSSION
To our knowledge, this is the largest report of the long- term 
follow- up of STN- DBS in a series of patients with severe, refrac-
tory OCD with long- lasting obsessions and compulsions. This 
paper reinforces the previous study of STN- DBS for OCD, 
which was recently updated at the long- term follow- up.23
Despite being the first randomised controlled study in psycho-
surgery, and despite publication in one of the highest- ranking 
journals, the STOC study did not have a relevant impact in 
psychiatry up to now. We were however highly impressed by the 
outcomes of our first patients, more so than in STN- DBS in PD as 
patients with OCD are younger, have a more severe impairment 
in quality of life than PD patients. As they do not have a degener-
ative progressive disorder, an efficacious symptomatic treatment 
will have life- long benefit. In this setting, after Prof Benabid had 
asked the French National Ethical Committee for authorisation 
to perform DBS in refractory OCD, the present study was aimed 
at looking at the long- term follow- up and safety.
Indeed, safety was the first concern in this population suffering 
from a non- degenerative disorder. Surgery was well tolerated in 
all patients except one who experienced a left thalamic contu-
sion responsible for mild partially reversible dysarthria and 
for another one who had a hardware- related complication. 
AEs related to stimulation were all reversible (see table 7) after 
decreasing the voltage. The active contacts were located into the 
anterior part of the STN in all cases, but in one patient, the stim-
ulation induced motor contraction at a low threshold, whereas 
the lead location was indeed into the anteromedial part of the 
STN.
No seizures were reported in our series, which contrasts with 
other studies that reported a high rate of seizures (5/24 reported 
by Luyten et al24). The low voltage used in our patient might be 
one of the explanations for that, associated with the fact that 
STN stimulation has been reported in animals and in epileptic 
patients to have a possible antiepileptic effect.25 26
The severity of OCD was significantly improved over time 
(mean decrease of the YBOCS: 53.4% at 24 months) as did the 
number of responders (14 out of 19 at 24 months). Our results 
Table 3 Effects on YBOCS and GAF
Patient
Baseline
YBOCS (O+C)
Baseline
GAF
YBOCS
6 m (% improvement)
YBOCS
12 m (% improvement)
YBOCS
24 m (% improvement)
GAF
24 m (% improvement)
1 18+19=37 26 12 (67) 21 (43) 18 (51) 67 (61)
2 18+17=35 36 26 (25) NA NA NA
3 16+20=36 32 7 (80) 7 (80) 5 (86) 85 (62)
4 15+15=30 36 20 (33) 20 (33) 18 (40) 68(47)
5 17+17=34 36 8 (76) 10 (70) 8 (76) 85(57)
6 14+15=29 36 10 (65) 6 (79) 12 (58) 56(35)
7 14+18=32 33 7 (78) 3 (90) 4 (87) 87(62)
8 20+20=40 33 28 (30) 16 (60) 14 (65) 58(43)
9 18+18=36 32 30 (16) 6 (83) 6 (83) 87(63)
10 17+15=32 41 21 (34) 28 (12) 28 (12) 48(14)
11 19+17=36 34 20 (44) 30 (16) 18 (50) 60(43)
12 17+16=33 30 2 (94) 2 (94) 2 (94) 87 (65)
13 18+20=38 30 20 (47) 22 (42) 23 (39) 50 (40)
14 16+16=32 35 26 (18) 26 (18) 27 (15) 50 (30)
15 16+18=34 40 31 (8) 30 (11) 22 (35) MD
16 15+18=33 31 31 (6) 32 (3) 29 (12) 36 (13)
17 15+16=31 38 29 (6) 28 (9) 29 (6) 40 (5)
18 12+13=25 40 11 (56) 12 (52) 7 (72) 98 (59)
19 15+15=30 37 15 (50) 14 (53) 15 (50) 68 (45)
Mean (SD) 33.31 (3.54) 34.52 (3.89) 18.63 (9.42) 17.38 (10.71) 15.83 (9.61) 66.47 (27.48)
Patient two disrupted follow- up in our centre due to personality disorders, the IPG was removed 3.5 years after implantation after request of the STOC Study PI.
GAF, Global Assessment Functioning; IPG, Internal Pulse Generator; STOC, Stimulation dans le Trouble Obsessionnel Compulsif; YBOCS, Yale and Brown Obsessive–Compulsive 
Scale.
Table 4 Statistical analysis of YBOCS and GAF at the group level
Baseline 6 months 12 months 24 months
Mean(SD) 95% CI Mean (SD) 95% CI % P value Mean (SD) 95% CI % P value Mean (SD) 95% CI %
P 
value
YBOCS total score 33.3 (3.5) 31.7–34.9 18.6 (9.4) 14.4–22.8 44 *** 16.8 (10.2) 12.2–21.4 49.4 *** 15.5 (9.4) 11.1–19.9 53.4 ***
Obsession score 16.3 (1.9) 15.2–17.3 7.1 (6.2) 4.3–9.9 56.5 ** 5.2 2.6–7.8 69 ** 5.8 (5.5) 2.9–8.6 64 **
Compulsion score 17 (1.9) 15.9–18.1 11.5 (5.9) 8.8–14.2 32.4 ** 11.6 8.2–15 32 ** 9.7 (4.7) 7.3–12.1 42 **
GAF score 34.5 (3.9) 32.8–36.2 NA NA 66.4 (18.8) 58–74.9 **
***p<0.0001; **p<0.0005.
GAF, Global Assessment Functioning; YBOCS, Yale and Brown Obsessive–Compulsive Scale.
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confirm the favourable long- term outcome reported by Mallet et 
al who showed that 9 out of 14 patients were full responders at 
the last follow- up, with a median improvement of 50%.23
Up to now, only one paper from our group has reported the 
outcome at a very long- term follow- up of an OCD case as a 
comorbidity in Gilles de la Tourette syndrome treated by noM- 
STN- DBS27 that illustrated the long- term efficacy of this tech-
nique applied on a new target, the noM- STN. In the present 
study, the same target located in the anteromedial STN was 
used in all patients and parameter settings were similar to those 
usually used in patients with PD. This could be seen as an advan-
tage of this target as the voltages used during chronic stimulation 
were quite low saving current drain and increasing battery life 
and thus decreasing cost and complications.
The results of the present study confirm also the value of DBS 
as a surgical technique to treat severe OCD with good outcomes 
at a long- term follow- up. The vast majority of patients world-
wide have been implanted in the anterior capsule or in the 
nucleus accumbens with similar results on the YBOCS. Denys 
et al28 reported a series of 16 patients who received a bilateral 
chronic stimulation above the nucleus accumbens, with 9 out 
of 16 being considered as responders at 84 weeks. During the 
double- blind phase, a significant difference was found in 14 out 
of 16 patients between the OFF and ON phase. Nuttin's group 29 
have also reported their long- term follow- up of DBS of the bed 
nucleus of the stria terminalis. The responder rate at 3 years was 
52% and improved over time to reach 65% at 6 years and was 
stable (60 %) at 9 years (but data were available only in 10 out 
of 24 patients). Some AEs were also reported.
Recently, a small series of patients have been implanted both 
into the anterior capsule and the STN, with four electrodes.30 
The result showed that DBS of the anterior capsule and STN 
were efficient to improve the severity of the OCD (reduction by 
53% and 46%, respectively, of the YBOCS, p: NS) with a better 
effect on mood for the anterior capsule and a better effect on 
cognitive flexibility for the STN, probably due to the modulation 
of two close but distinct neuronal networks.
Surprisingly, GAF was improved in most cases at 24 months, 
even in patients who were not considered as responders. This 
average good improvement is partly explained by the number 
of good responders. But it is likely that other factors such as the 
Figure 2 (A) Individual (all patients) YBOCS scores at baseline, 6, 12 
and 24 months postoperatively. (B) Averaged YBOCS scores and subscores 
for obsessions and compulsions at baseline, 6, 12 and 24 months 
postoperatively. YBOCS, Yale and Brown Obsessive–Compulsive Scale; **, 
p<0.0005; ***, p<0.0001.
Figure 3 (A) Individual (all patients) GAF scores at baseline and 
24 months postoperatively. (B) Averaged GAF scores at baseline and 
24 months postoperatively. GAF, Global Assessment Functioning. **, 
p<0.0005; ***, p<0.0001.
Table 5 Responders vs non- responders at a 24- month follow- up
Responders
(n=14/73.7%)
Non- responders
(n=5/26.3%) P value
  Gender (M/F) 2–12 5–0   0.0018
Age at onset (years) 10.7±8 18.4±2.3 NS
Age at surgery (years) 38.6±7.4 44.4±9.2 NS
Duration 18.9±7.2 26±11.2 NS
Type of OCD   
  C 7 3 NS
  W 5 1 NS
  A 2 0 NS
  H 0 1 NS
  R 3 2 NS
OCD type=C: doubt/checking; W: contamination/washing; A: aggressive; H: 
hoarding; R: repetitive, just right obsessions. A same patient can suffer from 
different types of OCD symptoms.
NS, no statistically significant difference; OCD, obsessive–compulsive disorder.
Table 6 Active contacts and parameters settings at the last follow- 
up (2 years)
Patient
Active contacts Voltage
(R/L)Right Left
1 1 5 1.2
2* 2 6 1
3 2 6 4
4 1 5 1.3/1.5
5 1 5 1.3
6 2 6 1.3
7 2 6 1.5
8 1 5 1.1
9 0–1– 4–5– 1.6
10 1–2– 5– 2.3/1
11 1+2– 5+6– 3.3
12 1 5 1.5
13 1–2– 5–6– 3.6
14 1–2– 5–6– 1.9
15 1–2– 5–6– 2.4
16 0–1– 4–5– 1.6
17 0–1– 4–5– 2.3
18 0–1– 4–5– 2
19 0–1– 4–5– 1.6
*Data available at 6 months postoperatively only.
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intense psychological support in this selected population might 
have played a role. Despites possible confounding factors, the 
severity of impairment in some functional aspects as revealed by 
a low mean GAF at baseline was dramatically improved at 24 
months, suggesting that STN- DBS was effective not only on the 
YBOCS score but also on functioning and daily life activities. It has 
already been shown that patients with OCD who were treated with 
DBS improved their scores on the WHO Quality of Life Scale in all 
domains, except for the social domain.31 A clinical trial dedicated 
to the study of quality of life after noM- STN- DBS has started and 
will address this issue (EQUOLOC study: NCT02844049).
No differences among responders vs non- responders were 
noticed regarding age at surgery and duration of the disease. 
However, the female gender was statistically more represented 
in the responder group as compared with non- responders. This 
factor was not reported as a predictive factor of good response in 
a recent meta- analysis,32 neither was the duration of the disease. 
However, we did not find any correlation between the late onset of 
the disease and good response to STN- DBS, in opposition to what 
has been reported.32
Regarding the position of active contacts, they were all located 
anteriorly, in a subregion of the STN in which cognitive and limbic 
neurons project. This strong anatomoclinical correlation is a major 
argument in favour of the use of STN, a well- defined anatomical 
target.
Two patients committed suicide, despite a very careful clinical 
evaluation before and after surgery. Suicidality is a complex situ-
ation in which several factors interfere. In a large Parkinsonian 
cohort followed in our institution for 23 years, suicide risk was 
<1% over a period of follow- up of 9 years on average.33 Suicide 
was more likely to occur during the first 3 years after STN- DBS 
surgery. The main risk factors were history of preoperative depres-
sion and suicidal ideation or attempts and higher depression scores 
on preoperative evaluation, arguing for selection bias. Surgery not 
only represents election bias, but can also be seen as a last chance by 
a patient, which may be dangerous as in these cases depression can 
be absent immediately before surgery that is creating hope. Decep-
tion based on unmet outcomes in this situation can favour reactive 
depression. It has been postulated that impulsivity triggered by 
STN- DBS might favour suicides directly via STN- DBS. However, 
suicides have been reported after surgery in different targets and in 
different diseases. For example, 2 of 16 patients with GPi (Internal 
Globus Pallidus)DBS in generalised dystonia without depression 
on preoperative evaluation committed suicide.34 In favour of bias 
as a key factor is also the fact that PD patients randomised into 
DBS or best medical treatment group did not show statistically 
significant differences in suicidal outcome and no difference was 
seen between STN or GPi as targets.35
Postoperative suicides remain a major issue. Future studies will 
have to address this particularly in OCD where depression disorder 
is the most frequent comorbidity and the rate of suicides is very 
high. Indeed, patients with OCD have an increased risk of both 
attempting suicide (OR=5.45) and dying by suicide (OR=9.83), 
compared with matched controls.36 A previous suicide attempt 
is the strongest predictor of death by suicide in an OCD cohort. 
Having a comorbid personality disorder and a substance use 
disorder also increases the risk of suicide in this population. As 
only the most severe and disabled patients are candidates for DBS 
surgery, one might expect even a higher suicide rate in such a 
biased population. Teams engaged in this surgery must be cogni-
zant of this risk and must carefully monitor probably for the first 3 
years after surgery, mood and suicide ideation.
This study has several limitations including mainly its uncon-
trolled design, the patient being aware of the condition of stimula-
tion. However, the already published STOC study highlighted via a 
robust controlled, cross- over, double- blind design the acute effects 
over a short 3- month period. Another limitation may be the lack 
of specific assessment of the potential comorbid anxiety disorder 
or depression. But the main objective of this cohort follow- up was 
to assess the long- term benefit of STN- DBS on OCD severity as 
reflected by the YBOCS score. Nevertheless, the YBOCS scale 
includes the assessment of the anxiety related to obsessions and 
compulsions, whereas the affective impact of STN- DBS has already 
been highlighted.37
The mechanism of action of the STN target is still not well 
known, due to the recent use of STN- DBS in OCD. However, 
the anteromedial subregion of the STN is seen as the cognitive 
and limbic part of the STN, linked to the orbitofrontal, rostral 
cingulate and dorsolateral prefrontal cortex.38 39 Those regions 
are of paramount importance as they are involved in the decision 
process and conflict resolution that are the core of OCD.40 One 
could hypothesise that the inhibition of the noM- STN, which is 
hyperactive in patients with OCD41 using high- frequency stimu-
lation, is likely to modulate this circuitry and would indeed allow 
to increase decisional impulsivity, and consequently, to decrease 
the need to accumulate of evidence as already suggested40 before 
taking any decision.
CONCLUSION
This study confirms that a new target, the noM- STN, can be 
used to treat patients with severe refractory OCD.
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